Physician profile
Robert A Price
NPI 1003911587
$10,020.20
in general payments reported to CMS, 2019-2025
65 companies · $1,811 in 2025
The $1,811 reported for 2025 was more than what 92% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $915 · 2020: $898 · 2021: $1,158 · 2022: $1,308 · 2023: $1,835 · 2024: $2,096 · 2025: $1,811.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,742.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,741.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,262.01 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,147.77 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $831.50 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Otsuka America Pharmaceutical, INC. | $618.72 | 2021-2025 | Rexulti |
| Amgen INC. | $590.68 | 2019-2025 | Repatha, Otezla, Repatha |
| Lilly USA, LLC | $560.41 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Abbott Laboratories | $414.89 | 2021-2025 | Freestyle Libre 3, Mitraclip |
| Pfizer INC. | $372.37 | 2019-2025 | |
| Amarin Pharma, INC. | $353.95 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $341.82 | 2019-2025 | Xifaxan, Trulance |
| Bayer Healthcare Pharmaceuticals INC. | $308.71 | 2021-2025 | |
| Dexcom, INC. | $305.99 | 2023-2025 | Dexcom G6 Transmitter |
| Glaxosmithkline, LLC. | $226.12 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novartis Pharmaceuticals Corporation | $207.44 | 2021-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $202.69 | 2019-2023 | Jardiance |
Show all 65 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Price listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.